Literature DB >> 7579984

The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour.

C Kiernan1, D Reeves, A Alborz.   

Abstract

The use of anti-psychotic medication with an adult population of people with learning disabilities and challenging behaviours was investigated as part of an epidemiological study covering seven district health authorities and corresponding local authorities in North West England. The study found a high rate of prescription of anti-psychotic drugs (48.1%). Chlorpromazine was the most frequently prescribed drug, followed by Thioridazine and Haloperidol. Three variables, psychiatric diagnosis, where the person was resident (hospital disturbed ward, hospital non-disturbed ward, hostel or family home) and district of origin were found to be significant determinants of prescriptions when all other variables were controlled. Of the variables reflecting individual characteristics those significantly related to prescription suggested that the socially disruptive effects of challenging behaviour were determining prescription. The results are discussed in the context of differing prescription practices across residence and district in the context of the management of socially disruptive behaviour.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579984     DOI: 10.1111/j.1365-2788.1995.tb00518.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  11 in total

Review 1.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

2.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

Review 3.  Pharmacists' medicines-related interventions for people with intellectual disabilities: a narrative review.

Authors:  Máire O'Dwyer; Arijana Meštrović; Martin Henman
Journal:  Int J Clin Pharm       Date:  2015-04-24

Review 4.  Are antipsychotic drugs the right treatment for challenging behaviour in learning disability?: The place of a randomised trial.

Authors:  R Ashcroft; B Fraser; M Kerr; Z Ahmed
Journal:  J Med Ethics       Date:  2001-10       Impact factor: 2.903

5.  Inter-Rater Reliability of the Diagnoses of Psychosis and Depression in Individuals with Intellectual Disabilities.

Authors:  S Einfeld; B Tonge; L Chapman; C Mohr; J Taffe; S Horstead
Journal:  J Appl Res Intellect Disabil       Date:  2007-09

Review 6.  Aggressive behaviour in adults with intellectual disability: defining the role of drug treatment.

Authors:  Patricia Oliver-Africano; Declan Murphy; Peter Tyrer
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

7.  Depression in adults with mild intellectual disability: role of stress, attributions, and coping.

Authors:  Sigan L Hartley; William E Maclean
Journal:  Am J Intellect Dev Disabil       Date:  2009-05

8.  Perampanel and challenging behaviour in intellectual disability and epilepsy: a management dilemma.

Authors:  Emily Dolton; Ansar Choudry
Journal:  Case Rep Psychiatry       Date:  2014-12-17

9.  Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.

Authors:  Carol Paton; Sumera Bhatti; Kiran Purandare; Ashok Roy; Tre Barnes
Journal:  BMJ Open       Date:  2016-12-05       Impact factor: 2.692

10.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.